

REPORT OF AN INFORMAL CONSULTATION ON SCHISTOSOMIASIS CONTROL

Geneva, Switzerland, 30 March - 1 April 2011











REPORT OF AN INFORMAL CONSULTATION ON SCHISTOSOMIASIS CONTROL

Geneva, Switzerland

30 March - 1 April 2011



WHO Library Cataloguing-in-Publication Data:

Report of an informal consultation on schistosomiasis control, Geneva, Switzerland, 30 March – 1 April 2011.

1. Schistosomiasis – prevention and control. 2. Schistosomiasis – drug therapy. 3. Neglected diseases. I. World Health Organization.

ISBN 978 92 4 150501 7

(NLM classification: WC 810)

© World Health Organization 2013

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications —whether for sale or for non-commercial distribution— should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland.

WHO/HTM/NTD/PCT/2013..3

Contents

Introd	luctory a	address	V			
Purpo	se of the	e consultation	vii			
	ıtive sun	•	vii			
		rategy and its limitations	vii			
Impac	et of prev	ventive chemotherapy on schistosomiasis	viii			
1.	Preve	ntive chemotherapy in schistosomiasis: defining objectives in different				
		miological settings – country summaries	1			
	1.1	China: controlling morbidity				
	1.2	Egypt: adapting the treatment strategy	1 3 5 7			
	1.3	Uganda: scaling up, and impacting on morbidity	5			
	1.4	West Africa: expanding control	7			
		1.4.1 Burkina Faso	7			
		1.4.2 Niger	8			
2.	Mapp	ing of schistosomiasis: defining the implementation unit for preventive				
		otherapy, and identifying levels of prevalence to determine the				
		priate regimen	10			
	2.1	Mapping the distribution of schistosomiasis: historical data, risk				
		mapping and rapid surveys	10			
	2.2	Validation of schistosomiasis distribution and mapping at country level	12			
	2.3	Considerations for targeting communities for treatment	14			
	2.4	Targeting schistosomiasis treatment at the sub-district level	16			
3.	Identi	fying the preventive chemotherapy strategy to achieve the objective for				
	each i	mplementation unit: treatment regimen, monitoring of progress, decision-				
	makir	ng regarding future treatment	18			
	3.1	The evolution of preventive chemotherapy for schistosomiasis	18			
		3.1.1 Going beyond the health system	19			
		3.1.2 Adjusting the treatment strategy	20			
		3.1.3 Going beyond morbidity control	21			
	3.2	Reducing the frequency of treatment	21			
	3.3	Community and school-based interventions for schistosomiasis control	22			
	3.4	Modifying strategies during the course of schistosomiasis control				
		programmes				
	3.5	Data requirements and reporting tools	27			
	3.6	Access to praziquantel for neglected tropical disease control				
		programmes	29			
4.	Asse	Assessment of schistosomiasis programme impact				
	4.1	Monitoring impact in schistosomiasis control programmes	30			
	4.2	Impact of schistosomiasis treatment: assessment of long-term follow-up	31			

5.	_	Integration of schistosomiasis control with other programmes for control of			
	negle	cted tropical diseases	33		
	5.1	Planning for control: best practices	33		
	5.2	Resources for control: large-scale support for implementation of			
		preventive chemotherapy	35		
	5.3	Schistosomiasis within the control plan for neglected tropical disease			
		in the WHO African Region	37		
		5.3.1 Regional strategy for control of schistosomiasis, 2001–2010	37		
		5.3.2 Status of schistosomiasis control in the region	37		
	5.4	Integrating schistosomiasis treatment into control programmes	38		
	5.5	Monitoring needs for control programmes: lessons from lymphatic			
		filariasis	40		
		5.5.1 Evolution of guidelines	42		
	5.6	Capacity building	42		
6.	Poir	nts raised during the discussions	43		
7.	Rec	ommendations for refining the control strategy	48		
	7.1	Setting objectives and defining the problem: mapping and identifying communities at risk	48		
	7.2	Maintenance strategies decision after the attack phase	50		
Anne	x 1. Age	enda	56		
Anne	x 2. List	of participants	60		

Introductory address

I warmly welcome you to Geneva and this Informal Consultation on Schistosomiasis Control. I am happy to see the room so full, and thank you for taking the time to participate.

There have been successes in schistosomiasis control, but the disease continues to be a public health problem. On 14 October 2010, WHO launched its first report on neglected tropical diseases – *Working to overcome the global impact of neglected tropical diseases* – which explains how much preventive chemotherapy has expanded. However, impediments to control include country programmes that do not always perform well; for example, that available drugs are not distributed regularly and the amount of praziquantel is limited.

The number of reported cases of schistosomiasis has been the same for the past 30 years or more, due to growth of the population and the fact that this growth is not responding to the increase in intervention. Many feel also that within the preventive chemotherapy package, schistosomiasis does not have the same political visibility as other neglected tropical diseases, whereas in fact schistosomiasis is the major tropical disease in Africa after malaria. The disease is a major public health issue associated with severe mortality and morbidity; it blocks the capacity to develop agriculture infrastructure, is linked with water development, and associated with underdevelopment and poverty.

There are successes in terms of increased funding – the United Kingdom's Department for International Development committed £25 million to fight schistosomiasis, the Global Health Initiative and the Gates-funded SCORE (Schistosomiasis Consortium for Operational Research and Evaluation)¹ initiative; and success in reducing disease prevalence was achieved in many countries (e.g. Uganda, Niger, Burkina Faso) and beyond the African continent.

Considering all the different schistosome species infecting humans, the disease has been controlled in many places, and in many cases transmission has been stopped. We should aim for a different goal: maybe we can change the way we address schistosomiasis. Perhaps we have been too conservative in the past in emphasizing only morbidity control and making policy-makers think that schistosomiasis cannot be eliminated in most endemic settings.

We are here to listen and to address schistosomiasis with policy changes you think possible.

Dr Lorenzo Savioli Director, WHO Department of Control of Neglected Tropical Diseases, WHO

-

¹ http://score.uga.edu/

I will go into more detail of what we expect of this Consultation. In 2001, when we laid down the control strategy in our Expert Committee report, we were rather conservative in approach. The aim was morbidity control and the main target group was school-aged children. We still stand by this, but in the meantime the whole area of preventive treatment has evolved.

There have been more donations for other diseases, and this has encouraged us to be more ambitious in our approach. Schistosomiasis has followed this, and there have been requests from the field for WHO to further tailor the strategy, particularly with regard to treatment of adults. Adults were always included, but there were not many details.

So we expect recommendations about what changes are needed in the strategy. Last year there was a meeting on praziquantel treatment in preschool children, and we know what is possible and what is not possible, and our main target group remains school-aged children. But what do we need to do for our adult populations? We know praziquantel is not widely available, so we may not be able to be as generous as with other drugs for other diseases. So we must anticipate that in the first few years praziquantel will not be as widely available as other drugs against other neglected diseases. So how do we move forward? We cannot penalize populations with schistosomiasis, so we have to be generous enough to respond to the needs of those who have the disease, yet we cannot be unnecessarily generous: we cannot waste praziquantel. What is the optimal use of praziquantel within the integrated strategy of preventive chemotherapy, such that

预览已结束,完整报告链接和二维码如

https://www.yunbaogao.cn/report/index/report?reportId=5_2824